Pliant Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Pliant Therapeutics (PLRX) has granted stock options to its newly appointed Chief Technical Officer, Delphine Imbert, Ph.D., as part of her employment package. The grant includes options to purchase 275,000 shares of common stock at an exercise price of $11.07 per share, matching the company's closing price on January 21, 2025.
The options will vest over a 4-year period, with 25% vesting after the first year and the remaining shares vesting monthly at a rate of 1/48th over the subsequent 36 months, contingent on continued employment. The options have a 10-year term and are subject to the Company's 2022 Inducement Plan terms.
Pliant Therapeutics (PLRX) ha concesso opzioni su azioni al suo nuovo Chief Technical Officer, Delphine Imbert, Ph.D., come parte del suo pacchetto di assunzione. La concessione include opzioni per acquistare 275.000 azioni ordinarie a un prezzo di esercizio di $11,07 per azione, corrispondente al prezzo di chiusura dell'azienda del 21 gennaio 2025.
Le opzioni matureranno nell'arco di un periodo di 4 anni, con il 25% che matura dopo il primo anno e le restanti azioni che matureranno mensilmente a un tasso di 1/48 nei successivi 36 mesi, a condizione della continuazione dell'impiego. Le opzioni hanno un termine di 10 anni e sono soggette ai termini del Piano di Induzione 2022 della Società.
Pliant Therapeutics (PLRX) ha concedido opciones sobre acciones a su nuevo Director Técnico, Delphine Imbert, Ph.D., como parte de su paquete de empleo. La concesión incluye opciones para comprar 275,000 acciones comunes a un precio de ejercicio de $11.07 por acción, coincidiendo con el precio de cierre de la compañía del 21 de enero de 2025.
Las opciones se consolidarán durante un período de 4 años, con el 25% consolidándose después del primer año y las acciones restantes consolidándose mensualmente a una tasa de 1/48 en los siguientes 36 meses, sujeto a la continuidad del empleo. Las opciones tienen un plazo de 10 años y están sujetas a los términos del Plan de Inducción 2022 de la Compañía.
Pliant Therapeutics (PLRX)는 새로 임명된 최고 기술 책임자(CTO)인 Delphine Imbert, Ph.D.에게 고용 패키지의 일환으로 스톡 옵션을 부여했습니다. 부여에는 275,000주의 보통주를 $11.07의 행사 가격으로 매수할 수 있는 옵션이 포함되어 있으며, 이는 2025년 1월 21일 회사의 종가와 일치합니다.
옵션은 4년 기간에 걸쳐 발생하며, 첫 번째 해가 지난 후 25%가 발생하고 나머지 주식은 이후 36개월 동안 매달 1/48 비율로 발생합니다. 이는 고용이 지속되어야 가능합니다. 옵션의 유효 기간은 10년이며 회사의 2022 유도 계획의 조건에 따릅니다.
Pliant Therapeutics (PLRX) a accordé des options d'achat d'actions à sa nouvelle Directrice Technique, Delphine Imbert, Ph.D., dans le cadre de son paquet de rémunération. L'octroi comprend des options pour acheter 275 000 actions ordinaires à un prix d'exercice de 11,07 $ par action, correspondant au prix de clôture de l'entreprise le 21 janvier 2025.
Les options seront acquises sur une période de 4 ans, avec 25 % acquises après la première année et les actions restantes acquises mensuellement à un taux de 1/48 sur les 36 mois suivants, sous réserve de la poursuite de l'emploi. Les options ont une durée de 10 ans et sont soumises aux termes du plan d'incitation 2022 de la société.
Pliant Therapeutics (PLRX) hat ihrem neuernannten Chief Technical Officer, Delphine Imbert, Ph.D., im Rahmen ihres Arbeitsvertrags Aktienoptionen gewährt. Die Gewährung umfasst Optionen zum Kauf von 275.000 Aktien zu einem Ausübungspreis von $11,07 pro Aktie, was dem Schlusskurs des Unternehmens am 21. Januar 2025 entspricht.
Die Optionen werden über einen 4-jährigen Zeitraum fällig, wobei 25% nach dem ersten Jahr und die verbleibenden Aktien monatlich mit einem Satz von 1/48 über die folgenden 36 Monate fällig werden, vorbehaltlich einer fortdauernden Anstellung. Die Optionen haben eine Laufzeit von 10 Jahren und unterliegen den Bedingungen des Induktionsplans der Gesellschaft von 2022.
- Strengthening of executive team with appointment of new Chief Technical Officer
- Implementation of performance-based compensation structure aligned with long-term company growth
- Potential future dilution of existing shareholders from 275,000 new stock options
SOUTH SAN FRANCISCO, Calif., Jan. 22, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), today announced that on January 21, 2025, it granted stock options to purchase an aggregate of 275,000 shares of common stock upon vesting to Delphine Imbert, Ph.D., the Company’s newly appointed Chief Technical Officer, as a material inducement to her employment.
The stock options that were granted are subject to an exercise price of
About Pliant Therapeutics, Inc.
Pliant Therapeutics is a late-stage biopharmaceutical company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases. Pliant's lead product candidate, bexotegrast (PLN-74809), is an oral, small molecule, dual selective inhibitor of αvß6 and αvß1 integrins that is in development in the lead indication for the treatment of idiopathic pulmonary fibrosis, or IPF. Bexotegrast has received Fast Track Designation and Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) and Orphan Drug Designation from the European Medicines Agency in IPF. Pliant has initiated BEACON-IPF, an adaptive Phase 2b/3 trial of bexotegrast in IPF. Pliant is conducting a Phase 1 study for its third clinical program, PLN-101095, a small molecule, dual-selective inhibitor of αvß8 and αvß1 integrins, that is being developed for the treatment of solid tumors. In addition, Pliant has received regulatory clearance for the conduct of a Phase 1 study of PLN-101325, a monoclonal antibody agonist of integrin α7β1 targeting muscular dystrophies.
For additional information, please visit: www.PliantRx.com. Follow us on social media X, LinkedIn, and Facebook.
Investor and Media Contact:
Christopher Keenan
Vice President, Investor Relations and Corporate Communications
Pliant Therapeutics, Inc.
ir@pliantrx.com
FAQ
How many stock options did Pliant Therapeutics (PLRX) grant to its new CTO?
What is the exercise price for PLRX's newly granted stock options?
What is the vesting schedule for PLRX's new stock options grant?
How long is the term of PLRX's newly granted stock options?
